These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37792132)

  • 41. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
    Su X; Peng DQ
    Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
    Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV
    J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipid-Lowering Agents.
    Hegele RA; Tsimikas S
    Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
    O'Donoghue ML; Rosenson RS; Gencer B; López JAG; Lepor NE; Baum SJ; Stout E; Gaudet D; Knusel B; Kuder JF; Ran X; Murphy SA; Wang H; Wu Y; Kassahun H; Sabatine MS;
    N Engl J Med; 2022 Nov; 387(20):1855-1864. PubMed ID: 36342163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program.
    Stoekenbroek RM; Kallend D; Wijngaard PL; Kastelein JJ
    Future Cardiol; 2018 Nov; 14(6):433-442. PubMed ID: 30375244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
    Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
    JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
    Ray KK; Raal FJ; Kallend DG; Jaros MJ; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Lawrence D; Friedman A; Garcia Conde L; Wright RS;
    Eur Heart J; 2023 Jan; 44(2):129-138. PubMed ID: 36331326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
    Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclisiran-New hope in the management of lipid disorders?
    Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
    J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The dawn of a new era of targeted lipid-lowering therapies.
    Tokgözoğlu L; Libby P
    Eur Heart J; 2022 Sep; 43(34):3198-3208. PubMed ID: 35051271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
    Wadström BN; Wulff AB; Pedersen KM; Nordestgaard BG
    Curr Atheroscler Rep; 2023 Nov; 25(11):795-803. PubMed ID: 37768410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives.
    Mohamed AA; Ray KK
    Curr Opin Cardiol; 2023 Nov; 38(6):527-532. PubMed ID: 37522763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.